NovaBone to Unveil First-of-Its-Kind Bioactive Wedge at AOFAS 2025 Annual Meeting in Savannah
Visit Booth #544 to Experience the Industry’s First Pre-contoured, Fully Resorbable Wedge, with 5-year Shelf-Life
SAVANNAH, Ga., Aug. 21, 2025 /PRNewswire/ — NovaBone, a pioneer in synthetic bone graft technologies, will showcase its groundbreaking Bioactive Pre-contoured Wedge (BPW) at the 2025 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Savannah, Georgia.
The Bioactive Pre-contoured Wedge is the first fully-synthetic, porous bioactive glass solution to come to market and is, specifically, designed with osteostimulation in mind. BPW is the first non-metal wedge that is classified as a device, prioritizing patient safety and intra-operative effectiveness. It is engineered to correct deformities and fill osseous defects, while providing a fully resorbable, bio-integrative scaffold that promotes and accelerates bone regeneration.
“NovaBone’s Bioactive Pre-contoured Wedge is an innovative solution for orthopedic and podiatric surgeons, leveraging our superiority in BioGlass manufacturing,” said Scott Day, Vice President of Marketing & Business Development at NovaBone. “This new wedge provides an efficacious and affordable alternative to metal. Additionally, because the wedges are manufactured in the USA and have a 5-year shelf life, they are easy to stock, which reduces reliance on vulnerable global supply chains, limits tariff exposure, and eliminates problematic lead times.”
Charles Cook, MD, Clinical Assistant Professor of Orthopedic Surgery at The University of North Texas Health Science Center, and author of a retrospective case study on BPW, said, “Its pre-contoured shape supports efficient surgical workflow, and may provide a safe and effective scaffold for new bone growth. This, then, ensures surgical site stability and minimizes graft failure. As surgeons, we need this product in our toolkit.”
Key benefits of the NovaBone Bioactive Pre-contoured Wedge include:
- First-to-market bioactive pre-contoured wedge, regulated as a Class II device
- Bioactive glass structure that claims both osteoconductivity and osteostimulation
- Fully resorbable and replaced by native bone—no need for implant removal
- More cost-effective than metal implants, with an astounding five-year shelf life
- Compatible with reconstructive plating and staple solutions
Visitors to Booth #544 will have the opportunity to try the wedge in a hands-on model, giving a tactile sense of its handling and anatomical placement. Additionally, the NovaBone team will be sharing insights and engaging in live science discussions.
With over 20 years of clinical heritage and more than two million devices implanted, NovaBone continues to redefine – and lead – patient healing through innovation, science, and surgeon-centric design.
About NovaBone
NovaBone Products, LLC is a leading innovator in synthetic bone graft technologies, offering a portfolio of bioactive solutions that support bone regeneration, healing, and repair. Founded on decades of research in bioactive glass science, NovaBone’s proprietary Bioglass® technology is both osteoconductive and osteostimulative—actively supporting the body’s natural healing process by signaling and recruiting bone-forming cells. With over 20 years of proven clinical use and more than two million devices implanted worldwide, NovaBone is trusted by orthopedic, neurosurgical, and dental professionals for safe, effective, and innovative bone regeneration solutions. All NovaBone products are manufactured in the USA and designed to deliver reliable outcomes for patients and surgeons alike. To learn more, visit www.novabone.com.
Media Contact:
Alexander Petti